Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11830380 | 0.76 | DRD2 (0.41) | GAA | |
| SCHEMBL9166295 | 0.75 | PTGS2 (0.56) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL5517558 | 0.75 | PTGS2 (0.52) | PTGS2PTGS1OPRK1HTTKMT2A | |
| SCHEMBL11794283 | 0.73 | PTGS2 (0.51) | PTGS2POLBPTGS1OPRK1HTT | |
| SCHEMBL2449128 | 0.73 | POLB (0.43) | GAACPA1POLBHTT | |
| SCHEMBL9296383 | 0.72 | CYP27A1 (0.43) | PTGS2PTGS1 | |
| SCHEMBL10550334 | 0.67 | — | — | |
| SCHEMBL31474284 | 0.66 | GAA (0.45) | GAAPOLBKMT2A | |
| SCHEMBL7678867 | 0.65 | NOS3 (0.43) | — | |
| SCHEMBL5242912 | 0.64 | CYP19A1 (0.43) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524964-B2 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-28 | — | — | US | disclosed |
| US-7524964-B2 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-28 | — | — | US | disclosed |
| EP-1863479-B1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS CROSS REFERENCE TO RELATED APPLICATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-10 | — | — | EP | disclosed |
| US-20080085899-A1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS | LIOTTA FINA | 2008-04-10 | — | — | US | disclosed |
| US-20080085899-A1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS | LIOTTA FINA | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085899-A1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS | CNR1, CNR2, GPR18 | PTGS2 443/4885PLG 3584/4885GAA 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.